To determine if CCR2+HSCs are the subset of cells responsible for the observed efficacy of the combinatorial therapy, we compared the therapeutic effect of bulk HSC + PD-1 vs. CCR2+HSC + PD-1 in tumor-bearing mice. Here, CCR2 is linked to neoplasm.